US9359360B2 - TLR agonists - Google Patents
TLR agonists Download PDFInfo
- Publication number
- US9359360B2 US9359360B2 US13/682,208 US201213682208A US9359360B2 US 9359360 B2 US9359360 B2 US 9359360B2 US 201213682208 A US201213682208 A US 201213682208A US 9359360 B2 US9359360 B2 US 9359360B2
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- formula
- compounds
- tlr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000556 agonist Substances 0.000 title abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 210000004027 cell Anatomy 0.000 claims abstract description 12
- 210000001163 endosome Anatomy 0.000 claims abstract description 6
- -1 hydroxyC1-6alkylene Chemical group 0.000 claims description 65
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 150000002978 peroxides Chemical class 0.000 claims description 4
- 229940092253 ovalbumin Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010058846 Ovalbumin Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 18
- 231100000252 nontoxic Toxicity 0.000 abstract description 9
- 230000003000 nontoxic effect Effects 0.000 abstract description 9
- 241000124008 Mammalia Species 0.000 abstract description 7
- 230000019491 signal transduction Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000003308 immunostimulating effect Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 230000005923 long-lasting effect Effects 0.000 abstract description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 34
- 108020000411 Toll-like receptor Proteins 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- SHNIBVWXUOEWTA-UHFFFAOYSA-N 4-[[6-amino-2-(2-methoxyethoxy)-8-oxo-7h-purin-9-yl]methyl]benzaldehyde Chemical compound C12=NC(OCCOC)=NC(N)=C2N=C(O)N1CC1=CC=C(C=O)C=C1 SHNIBVWXUOEWTA-UHFFFAOYSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 229940124614 TLR 8 agonist Drugs 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- YYCDGEZXHXHLGW-UHFFFAOYSA-N 6-amino-9-benzyl-2-(2-methoxyethoxy)-7h-purin-8-one Chemical compound C12=NC(OCCOC)=NC(N)=C2NC(=O)N1CC1=CC=CC=C1 YYCDGEZXHXHLGW-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- NNISWFCIZCAIRC-PKNBQFBNSA-N C/N=N/C1=NC=C(C(C)=O)C=C1 Chemical compound C/N=N/C1=NC=C(C(C)=O)C=C1 NNISWFCIZCAIRC-PKNBQFBNSA-N 0.000 description 3
- 0 CC.CC.[1*]CC1=NC(N)=C2N=C(O)N(CC3=CC=CC=C3)C2=N1 Chemical compound CC.CC.[1*]CC1=NC(N)=C2N=C(O)N(CC3=CC=CC=C3)C2=N1 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 3
- 229910003827 NRaRb Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940124615 TLR 7 agonist Drugs 0.000 description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 235000013902 inosinic acid Nutrition 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229950000844 mizoribine Drugs 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- UEWSIIBPZOBMBL-UHFFFAOYSA-N 5-hydroxyimidazole-4-carboxamide Chemical compound NC(=O)C1=C([O-])[NH2+]C=N1 UEWSIIBPZOBMBL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001669 calcium Chemical class 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 150000005323 carbonate salts Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- DEEGXIFXZAYKSF-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[[6-amino-2-(2-methoxyethoxy)-8-oxo-7h-purin-9-yl]methyl]benzoate Chemical compound C12=NC(OCCOC)=NC(N)=C2N=C(O)N1CC(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O DEEGXIFXZAYKSF-UHFFFAOYSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- LDKSCZJUIURGMW-UHFFFAOYSA-N 1-isothiocyanato-3-methylsulfanylpropane Chemical group CSCCCN=C=S LDKSCZJUIURGMW-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- RGNOTKMIMZMNRX-XVFCMESISA-N 2-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-one Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RGNOTKMIMZMNRX-XVFCMESISA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical compound C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- VZOAGHRMLRLXBE-UHFFFAOYSA-N 4-[(2,6-dichloropurin-9-yl)methyl]benzonitrile Chemical compound C12=NC(Cl)=NC(Cl)=C2N=CN1CC1=CC=C(C#N)C=C1 VZOAGHRMLRLXBE-UHFFFAOYSA-N 0.000 description 1
- ATISKRYGYNSRNP-UHFFFAOYSA-N 4-[[6-amino-2-(2-methoxyethoxy)-8-oxo-7h-purin-9-yl]methyl]benzoic acid Chemical compound C12=NC(OCCOC)=NC(N)=C2NC(=O)N1CC1=CC=C(C(O)=O)C=C1 ATISKRYGYNSRNP-UHFFFAOYSA-N 0.000 description 1
- LEJUJCWPYINXEB-UHFFFAOYSA-N 4-[[6-amino-2-(2-methoxyethoxy)purin-9-yl]methyl]benzonitrile Chemical compound C12=NC(OCCOC)=NC(N)=C2N=CN1CC1=CC=C(C#N)C=C1 LEJUJCWPYINXEB-UHFFFAOYSA-N 0.000 description 1
- LDMVWEVNROLMHZ-UHFFFAOYSA-N 4-[[6-amino-8-bromo-2-(2-methoxyethoxy)purin-9-yl]methyl]benzonitrile Chemical compound C12=NC(OCCOC)=NC(N)=C2N=C(Br)N1CC1=CC=C(C#N)C=C1 LDMVWEVNROLMHZ-UHFFFAOYSA-N 0.000 description 1
- RUBGVJBUQLBBCN-UHFFFAOYSA-N 4-[[6-amino-8-methoxy-2-(2-methoxyethoxy)purin-9-yl]methyl]benzaldehyde Chemical compound C12=NC(OCCOC)=NC(N)=C2N=C(OC)N1CC1=CC=C(C=O)C=C1 RUBGVJBUQLBBCN-UHFFFAOYSA-N 0.000 description 1
- BAXBGOILCIVNDA-UHFFFAOYSA-N 4-[[6-amino-8-methoxy-2-(2-methoxyethoxy)purin-9-yl]methyl]benzonitrile Chemical compound C12=NC(OCCOC)=NC(N)=C2N=C(OC)N1CC1=CC=C(C#N)C=C1 BAXBGOILCIVNDA-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical class BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical class IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- YWXZCUWRUHSVKU-UHFFFAOYSA-N BrBr.C.COCCOC1=NC(N)=C2N=C(Br)N(CC3=CC=C(C#N)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C#N)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C(=O)OC)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C(=O)OC)C=C3)C2=N1.COCCOC1=NC(N)=C2N=CN(CC3=CC=C(C#N)C=C3)C2=N1.C[Si](C)(C)I.ClC1=NC(Cl)=C2N=CNC2=N1.N#CC1=CC=C(CN2C=NC3=C(Cl)N=C(Cl)N=C32)C=C1.N#CC1=CC=C(CN2C=NC3=C(N)N=C(Cl)N=C32)C=C1 Chemical compound BrBr.C.COCCOC1=NC(N)=C2N=C(Br)N(CC3=CC=C(C#N)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C#N)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C(=O)OC)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C(=O)OC)C=C3)C2=N1.COCCOC1=NC(N)=C2N=CN(CC3=CC=C(C#N)C=C3)C2=N1.C[Si](C)(C)I.ClC1=NC(Cl)=C2N=CNC2=N1.N#CC1=CC=C(CN2C=NC3=C(Cl)N=C(Cl)N=C32)C=C1.N#CC1=CC=C(CN2C=NC3=C(N)N=C(Cl)N=C32)C=C1 YWXZCUWRUHSVKU-UHFFFAOYSA-N 0.000 description 1
- CLXVWCZFZPMTLT-PQULTTOZSA-N C/N=N/C(=O)CCSC.C/N=N/C1=NC=C(C(C)=O)C=C1.CC(=O)CCCC1=CC=C(N2C(=O)CC(C)C2=O)C=C1.CC(=O)CCCCCCC(=O)CCN1C(=O)CC(C)C1=O.CC(=O)NC1=CC=C(N2C(=O)CC(C)C2=O)C=C1.CC(=O)NC1=CC=C(N2C(=O)CC(C)C2=O)C=C1 Chemical compound C/N=N/C(=O)CCSC.C/N=N/C1=NC=C(C(C)=O)C=C1.CC(=O)CCCC1=CC=C(N2C(=O)CC(C)C2=O)C=C1.CC(=O)CCCCCCC(=O)CCN1C(=O)CC(C)C1=O.CC(=O)NC1=CC=C(N2C(=O)CC(C)C2=O)C=C1.CC(=O)NC1=CC=C(N2C(=O)CC(C)C2=O)C=C1 CLXVWCZFZPMTLT-PQULTTOZSA-N 0.000 description 1
- YSIKDZDSVRQXRK-UHFFFAOYSA-N COCCOC1=NC(N)=C2N=C(O)N(CC3=CC=C(C(=O)O)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(O)N(CC3=CC=C(C(=O)ON4C(=O)CCC4=O)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(O)N(CC3=CC=C(C=O)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C=O)C=C3)C2=N1 Chemical compound COCCOC1=NC(N)=C2N=C(O)N(CC3=CC=C(C(=O)O)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(O)N(CC3=CC=C(C(=O)ON4C(=O)CCC4=O)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(O)N(CC3=CC=C(C=O)C=C3)C2=N1.COCCOC1=NC(N)=C2N=C(OC)N(CC3=CC=C(C=O)C=C3)C2=N1 YSIKDZDSVRQXRK-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- NQZSHJVZFHCDLR-UHFFFAOYSA-N methyl 4-[[6-amino-8-methoxy-2-(2-methoxyethoxy)purin-9-yl]methyl]benzoate Chemical compound C12=NC(OCCOC)=NC(N)=C2N=C(OC)N1CC1=CC=C(C(=O)OC)C=C1 NQZSHJVZFHCDLR-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950006081 taribavirin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Definitions
- PAMPs pathogen associated molecular patterns
- PAMPs include peptidoglycans, lipotechoic acids from gram-positive cell walls, the sugar mannose (which is common in microbial carbohydrates but rare in humans), bacterial DNA, double-stranded RNA from viruses, and glucans from fungal cell walls.
- TLRs Toll-like Receptors
- TLR7 and TLR9 recognize and respond to imiquimod and immunostimulatory CpG oligonucleotides (ISS-ODN), respectively.
- the synthetic immunomodulator R-848 activates both TLR7 and TLR8. While TLR stimulation initiates a common signaling cascade (involving the adaptor protein MyD88, the transcription factor NF-kB, and pro-inflammatory and effector cytokines), certain cell types tend to produce certain TLRs. For example, TLR7 and TLR9 are found predominantly on the internal faces of endosomes in dendritic cells (DCs) and B lymphocytes (in humans; mouse macrophages express TLR7 and TLR9). TLR8, on the other hand, is found in human blood monocytes. (See Hornung et al., J Immunol, 168:4531-4537 (2002)).
- Interferons are also involved in the efficient induction of an immune response, especially after viral infection (Brassard et al., J. Leukoc Biol, 71:568-581 (2002).) However, many viruses produce a variety of proteins that block interferon production or action at various levels. Antagonism of interferon is believed to be part of a general strategy to evade innate, as well as adaptive immunity. (See Levy et al., Cytokine Growth Factor Rev, 12:143-156 (2001).) While TLR agonists (TLR-L) may be sufficiently active for some methods of treatment, in some instances the microbial interferon antagonists could mitigate the adjuvant effects of synthetic TLR-L.
- the present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them.
- the compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.
- the compounds of the invention include a pharmacophore covalently bound to an auxiliary group. Accordingly there is provided a compound of the invention which is a compound of formula (I):
- X 1 is —O—, —S—, or —NR c —;
- R c hydrogen, C 1-10 alkyl, or C 1-10 alkyl substituted by C 3-6 -cycloalkyl, or R c and R 1 taken together with the nitrogen atom can form a heterocyclic ring or a substituted heterocyclic ring, wherein the substituents are hydroxy, C 1-6 alkyl, hydroxyC 1-6 alkylene, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkylene, or cyano;
- R 1 is (C 1 -C 10 )alkyl, substituted (C 1 -C 10 )alkyl, C 6-10 aryl, or substituted C 6-10 aryl, C 5-9 heterocyclic, substituted C 5-9 heterocyclic;
- each R 2 is independently hydrogen, —OH, (C 1 -C 6 )alkyl, substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, substituted (C 1 -C 6 )alkoxy, —C(O)—(C 1 -C 6 )alkyl (alkanoyl), substituted —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl (aroyl), substituted —C(O)—(C 6 -C 10 )aryl, —C(O)OH (carboxyl), —C(O)O(C 1 -C 6 )alkyl (alkoxycarbonyl), substituted —C(O)O(C 1 -C 6 )alkyl, —NR a R b , —C(O)NR a R b (carbamoyl), substituted
- each R a and R b is independently hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkanoyl, hydroxy(C 1 -C 6 )alkyl, aryl, aryl(C 1 -C 6 )alkyl, Het, Het (C 1 -C 6 )alkyl, or (C 1 -C 6 )alkoxycarbonyl;
- X 2 is a bond or a linking group; and R 3 is an auxiliary group;
- the auxiliary groups can include organic molecules, composed of carbon, oxygen, hydrogen, nitrogen, sulfur, phosphorus atoms. These groups are not harmful to body tissues (e.g., they are non-toxic, and/or do not cause inflammation).
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.
- the invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the activity of TLR agonists is implicated and its action is desired, comprising administering to a mammal in need of such therapy, an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
- pathological conditions or symptoms that are suitable for treatment include cancers, treatment for bacterial or viral diseases, treating autoimmune diseases, and treating Crohn's Disease.
- the compounds of the invention can also be used as or to prepare vaccines against bacteria, viruses, cancer cells, cancer specific peptides, enhancers of monoclonal antibodies against cancer, a CNS stimulant, or for biodefense.
- the invention provides a compound of formula (I) for use in medical therapy (e.g., for use as an anti-cancer agent, treatment for bacterial diseases, treatment for viral diseases, such as hepatitis C and hepatitis B, Crohn's Disease, and as therapeutic agents for treating immunologic disease). Furthermore, it is suggested that compounds of formula (I) will prevent carcinogenesis by hepatitis C and hepatitis B, as well as the use of a compound of formula (I) for the manufacture of a medicament useful for the treatment of cancer, viral diseases, Crohn's Disease, and immunologic disorders in a mammal, such as a human.
- medical therapy e.g., for use as an anti-cancer agent, treatment for bacterial diseases, treatment for viral diseases, such as hepatitis C and hepatitis B, Crohn's Disease, and as therapeutic agents for treating immunologic disease.
- compounds of formula (I) will prevent carcinogenesis by hepatitis C and hepatitis B, as well
- the present invention provides a method for treating a viral infection in a mammal by administering a TLR agonist compound of formula (I).
- the viral infection can be caused by an RNA virus, a product of the RNA virus that acts as a TLR agonist and/or a DNA virus.
- a specific DNA virus for treatment is the Hepatitis B virus.
- the present invention provides a method for treating cancer by administering an effective amount of a TLR agonist compound of formula (I).
- the cancer can be an interferon sensitive cancer, such as, for example, a leukemia, a lymphoma, a myeloma, a melanoma, or a renal cancer.
- the present invention provides a method of treating an autoimmune disease by administering a therapeutically effective amount of a TLR agonist compound of formula (I) or a pharmaceutically acceptable salt of such a compound.
- a specific autoimmune disease is Multiple Sclerosis, lupus, rheumatoid arthritis and the like.
- the present invention provides a method of treating Crohn's Disease by administering a TLR agonist compound of formula (I).
- the TLR agonists can be a homofunctional TLR agonist polymer and can consist of a TLR-7 agonist or a TLR-8 agonist.
- the TLR7 agonist can be a 7-thia-8-oxoguanosinyl (TOG) moiety, a 7-deazaguanosinyl (7DG) moiety, a resiquimod moiety, or an imiquimod moiety.
- the TLR8 agonist can be a resiquimod moiety.
- the TLR agonist is a heterofunctional TLR agonist polymer.
- the heterofunctional TLR agonist polymer can include a TLR-7 agonist and a TLR-8 agonist or a TLR-9 agonist or all three agonists.
- the heterofunctional TLR agonist polymer can include a TLR-8 agonist and a TLR-9 agonist.
- the invention also provides processes and intermediates disclosed herein that are useful for preparing compounds of formula (I) or salts thereof.
- FIG. 1 is a graphic illustration of the absorption chromophore (at ⁇ 350 nm) of a compound of formula I (OVA/IV150 Conjugate).
- FIG. 2 is a graphic illustration of the stimulation of bone marrow derived dendritic cells (BMDC).
- FIG. 3 illustrates the conjugation of a TLR7 agonist, UC-1V150, to mouse serum albumin (MSA). The success of conjugation is indicated by UV spectroscopy.
- the UC-1V150 to MSA ratio is approximately 5:1
- FIGS. 4A and B illustrate that the UC-1V150 and MSA conjugates activate both murine bone marrow-derived macrophages ( 4 A) and human peripheral blood mononuclear cells ( 4 B).
- Cells were incubated with various concentrations of the compound from 0.5 nM to 10 ⁇ M in BMDM or from 0.1 to 10 ⁇ M in PBMC. Culture supernatants were harvested after 24 h and cytokine levels were analyzed by Luminex.
- FIGS. 5A, 5B, 5C, and 5D illustrate the increased potency and duration of effect of UC-1V150/MSA.
- C57BL/6 mice were injected (i.v.) with (A) 0.1 micromole of SM-360320, a TLR7 ligand, or (B) equivalent amount of a TLR7 agonist UC-1V150 (aldehyde-modified SM-360320) or UC-1V150/MSA to 500 ⁇ g MSA per mouse.
- Serum samples were collected at the indicated time points and cytokine levels were analyzed by Luminex.
- MSA mouse serum albumin.
- the effect from the original TLR7 ligand, SM-360320 lasted for only 2 hours whereas UC-1V150/MSA has extended the effect to at least 6 hours.
- FIG. 6 illustrates the effects of UC-1V150 conjugated with inactivated SIV ( 6 A) or with OVA in combination with ODN ( 6 B).
- Myeloid BMDC were incubated for 24 hr with various conditions at 0.1 ⁇ g/ml as indicated.
- IL-12 levels in the cell supernatant were measured by ELISA.
- FIGS. 7A and 7B illustrates an increased potency of UC-1V150/MSA.
- C57BL/6 mice were i.v. injected with 380 nmole of SM-360320 or UC-1V150, or 500 ⁇ g of UC-1V150/MSA (equivalent to 3.8 nmole UC-1V150) per mouse.
- Serum samples were collected after 2 h and cytokine levels were analyzed by Luminex. To achieve the similar effect, at least 100-fold higher concentration of either UC-1V150 or SM-360320 was required as compared to that of UC-1V150/MSA.
- FIG. 8 is an illustration of the uv spectrum of a double-conjugate, (OVA/IV150/1043).
- FIG. 9 is an illustration of the induction of IL-12 in BMDC using OVA/ODN/IV150 conjugates.
- FIG. 10 illustrates direct conjugation of SIV Particles to the IA compound IV150.
- FIG. 11 illustrates the ability to prepare compounds of the invention with virus particles attached to a compound having formula IA and the TLR agonist activity of the compounds.
- FIG. 12 illustrates the molecular areas of specificity for antibodies raised against the conjugates containing a linker and a TLR ligand.
- FIGS. 13A and 13B illustrate the distinction between the four substances applied to the respective lanes on a gel in a Western plot analysis.
- the gel membrane was probed with anti-ovalbumin (anti-OVA) antibody and all lanes gave a positive band, indicating that OVA was detected in all lanes, as expected.
- the gel membrane was probed with the selective antibody raised to the TLR ligand portion of the conjugate, and therefore only lane 4 was positive, confirming the specificity of the antibody for the TLR ligand.
- auxiliary groups include side chains that increase solubility, such as, for example, groups containing morpholino, piperidino, pyrrolidino, or piperazino rings and the like; amino acids, polymers of amino acids (proteins or peptides), e.g., dipeptides or tripeptides, and the like; carbohydrates (polysaccharides), nucleotides such as, for example, PNA, RNA and DNA, and the like; polymers of organic materials, such as, for example, polyethylene glycol, poly-lactide and the like; monomeric and polymeric lipids; insoluble organic nanoparticles; non-toxic body substances such as, for example, cells, lipids, vitamins, co-factors, antigens such as, for example microbes, such as, for example, viruses, bacteria, fungi, and the like.
- the antigens can include inactivated whole organisms, or sub-components thereof and the like.
- the compounds of the invention can be prepared using compounds having formula (IA):
- X is a group that can react to form a bond to the linking group or can react to form a bond to the auxiliary group.
- a specific group of compounds having formula (IA) are disclosed in U.S. Pat. No. 6,329,381.
- halo is fluoro, chloro, bromo, or iodo.
- Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as “propyl” embraces only the straight chain radical, a branched chain isomer such as “isopropyl” being specifically referred to.
- Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.
- Heteroaryl encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (C 1 -C 4 )alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
- Processes for preparing compounds of formula I or for preparing intermediates useful for preparing compounds of formula I are provided as further embodiments of the invention.
- Intermediates useful for preparing compounds of formula I are also provided as further embodiments of the invention.
- salts may be appropriate.
- acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
- Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
- Acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
- a sufficiently basic compound such as an amine
- a suitable acid affording a physiologically acceptable anion.
- Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
- Alkyl includes straight or branched C 1-10 alkyl groups, e.g., methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, 1-methylpropyl, 3-methylbutyl, hexyl, and the like.
- Lower alkyl includes straight or branched C 1-6 alkyl groups, e.g., methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, and the like.
- C 1-6 alkyl groups e.g., methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, and the like.
- alkylene refers to a divalent straight or branched hydrocarbon chain (e.g. ethylene —CH 2 —CH 2 —).
- Cycloalkyl includes groups such as, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, and alkyl-substituted C 3-7 cycloalkyl group, preferably straight or branched C 1-6 alkyl group such as methyl, ethyl, propyl, butyl or pentyl, and C 5-7 cycloalkyl group such as, cyclopentyl or cyclohexyl, and the like.
- Lower alkoxy includes C 1-6 alkoxy groups, such as methoxy, ethoxy or propoxy, and the like.
- Lower alkanoyl includes C 1-6 alkanoyl groups, such as formyl, acetyl, propanoyl, butanoyl, pentanoyl or hexanoyl, and the like.
- C 7-11 aroyl includes groups such as benzoyl or naphthoyl;
- Lower alkoxycarbonyl includes C 2-7 alkoxycarbonyl groups, such as methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl, and the like.
- Lower alkylamino group means amino group substituted by C 1-6 alkyl group, such as, methylamino, ethylamino, propylamino, butylamino, and the like.
- Di(lower alkyl)amino group means amino group substituted by the same or different and C 1-6 alkyl group (e.g. dimethylamino, diethylamino, ethylmethylamino).
- Lower alkylcarbamoyl group means carbamoyl group substituted by C 1-6 alkyl group (e.g. methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl).
- Di(lower alkyl)carbamoyl group means carbamoyl group substituted by the same or different and C 1-6 alkyl group (e.g. dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl).
- Halogen atom means halogen atom such as fluorine atom, chlorine atom, bromine atom or iodine atom.
- Aryl refers to a C 6-10 monocyclic or fused cyclic aryl group, such as phenyl, indenyl, or naphthyl, and the like.
- Heterocyclic refers to monocyclic saturated heterocyclic groups, or unsaturated monocyclic or fused heterocyclic group containing at least one heteroatom, e.g., 0-3 nitrogen atoms (—NR d —), 0-1 oxygen atom (—O—), and 0-1 sulfur atom (—S—).
- saturated monocyclic heterocyclic group includes 5 or 6 membered saturated heterocyclic group, such as tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperidyl, piperazinyl or pyrazolidinyl.
- Non-limiting examples of unsaturated monocyclic heterocyclic group includes 5 or 6 membered unsaturated heterocyclic group, such as furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thienyl, pyridyl or pyrimidinyl.
- Non-limiting examples of unsaturated fused heterocyclic groups includes unsaturated bicyclic heterocyclic group, such as indolyl, isoindolyl, quinolyl, benzothizolyl, chromanyl, benzofuranyl, and the like.
- heterocyclic rings include 5 or 6 membered saturated heterocyclic rings, such as 1-pyrrolidinyl, 4-morpholinyl, 1-piperidyl, 1-piperazinyl or 1-pyrazolidinyl, 5 or 6 membered unsaturated heterocyclic rings such as 1-imidazolyl, and the like.
- the alkyl, aryl, heterocyclic groups of R 1 can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include lower alkyl; cycloalkyl, hydroxyl; hydroxy C 1-6 alkylene, such as hydroxymethyl, 2-hydroxyethyl or 3-hydroxypropyl; lower alkoxy; C 1-6 alkoxy C 1-6 alkyl, such as 2-methoxyethyl, 2-ethoxyethyl or 3-methoxypropyl; amino; alkylamino; dialkyl amino; cyano; nitro; acyl; carboxyl; lower alkoxycarbonyl; halogen; mercapto; C 1-6 alkylthio, such as, methylthio, ethylthio, propylthio or butylthio; substituted C 1-6 alkylthio, such as methoxyethylthio, methylthioethylthio, hydroxyeth
- the alkyl, aryl, heterocyclic groups of R 2 can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include hydroxyl; C 1-6 alkoxy, such as methoxy, ethoxy or propoxy; carboxyl; C 2-7 alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl) and halogen.
- the alkyl, aryl, heterocyclic groups of R c can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include C 3-6 cycloalkyl; hydroxyl; C 1-6 alkoxy; amino; cyano; aryl; substituted aryl, such as 4-hydroxyphenyl, 4-methoxyphenyl, 4-chlorophenyl or 3,4-dichlorophenyl; nitro and halogen.
- the heterocyclic ring formed together with R c and R 1 and the nitrogen atom to which they are attached can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include C 1-6 alkyl; hydroxy C 1-6 alkylene; C 1-6 alkoxy C 1-6 alkylene; hydroxyl; C 1-6 alkoxy; and cyano.
- amino acid as used herein, comprises the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g.
- the term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g.
- acetyl or benzyloxycarbonyl as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a (C 1 -C 6 )alkyl, phenyl or benzyl ester or amide; or as an -methylbenzyl amide).
- suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, T. W. Greene, Protecting Groups In Organic Synthesis ; Wiley: New York, 1981, and references cited therein).
- An amino acid can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.
- TLR toll-like receptor
- PAMPs pathogen associated molecular patterns
- TLR agonist refers to a molecule that binds to a TLR and antagonizes the receptor.
- Synthetic TLR agonists are chemical compounds that are designed to bind to a TLR and activate the receptor.
- Exemplary novel TLR agonists provided herein include “TLR-7 agonist” “TLR-8 agonist” and “TLR-9 agonist.”
- nucleic acid refers to DNA, RNA, single-stranded, double-stranded, or more highly aggregated hybridization motifs, and any chemical modifications thereof. Modifications include, but are not limited to, those providing chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole.
- Such modifications include, but are not limited to, peptide nucleic acids (PNAs), phosphodiester group modifications (e.g., phosphorothioates, methylphosphonates), 2′-position sugar modifications, 5-position pyrimidine modifications, 7-position purine modifications, 8-position purine modifications, 9-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, methylations, unusual base-pairing combinations such as the isobases, isocytidine and isoguanidine and the like.
- Nucleic acids can also include non-natural bases, such as, for example, nitroindole. Modifications can also include 3′ and 5′ modifications such as capping with a BHQ, a fluorophore or another moiety.
- a specific value for X 1 is a sulfur atom, an oxygen atom or —NR c —.
- Another specific X 1 is a sulfur atom.
- Another specific X 1 is an oxygen atom.
- Another specific X 1 is —NR c —.
- Another specific X 1 is —NH—.
- R c is hydrogen, C 1-4 alkyl or substituted C 1-4 alkyl.
- R 1 and R c taken together is when they form a heterocyclic ring or a substituted heterocyclic ring.
- R 1 and R c taken together is substituted or unsubstituted morpholino, piperidino, pyrrolidino, or piperazino ring.
- R 1 is hydrogen, C 1-4 alkyl, or substituted C 1-4 alkyl.
- R 1 is 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, ethoxymethyl, 2-ethoxyethyl, methylthiomethyl, 2-methylthioethyl, 3-methylthiopropyl, 2-fluoroethyl, 3-fluoropropyl, 2,2,2-trifluoroethyl, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, methoxycarbonylmethyl, 2-methoxycarbonylethyl, 3-methoxycarbonylpropyl, benzyl, phenethyl, 4-pyridylmethyl, cyclohexylmethyl, 2-thienylmethyl, 4-methoxyphenylmethyl, 4-hydroxyphenylmethyl, 4-fluorophenylmethyl, or 4-chlorophen
- R 1 is hydrogen, CH 3 —, CH 3 —CH 2 —, CH 3 CH 2 CH 2 —, hydroxyC 1-4 alkylene, or C 1-4 alkoxyC 1-4 alkylene.
- R 1 Another specific value for R 1 is hydrogen, CH 3 —, CH 3 —CH 2 —, CH 3 —O—CH 2 CH 2 — or CH 3 —CH 2 —O—CH 2 CH 2 —.
- R 2 is hydrogen, halogen, or C 1-4 alkyl.
- R 2 is hydrogen, chloro, bromo, CH 3 —, or CH 3 —CH 2 —.
- substituents for substitution on the alkyl, aryl or heterocyclic groups are hydroxy, C 1-6 alkyl, hydroxyC 1-6 alkylene, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkylene, C 3-6 cycloalkyl, amino, cyano, halogen, or aryl.
- a specific value for X 2 is a bond or a chain having up to about 24 atoms; wherein the atoms are selected from the group consisting of carbon, nitrogen, sulfur, non-peroxide oxygen, and phosphorus.
- X 2 is a bond or a chain having from about 4 to about 12 atoms.
- X 2 is a bond or a chain having from about 6 to about 9 atoms.
- a specific auxiliary group is an amino acid, a carbohydrate, a peptide, an antigen, a nucleic acid, a body substance, or a microbe.
- a specific peptide has from 2 to about 20 amino acid residues.
- Another specific peptide has from 10 to about 20 amino acid residues.
- a specific auxiliary group is a carbohydrate.
- a specific nucleic acid is DNA, RNA or PNA.
- a specific body substance is a cell, lipid, vitamin, or co-factor.
- Another specific body substance is a cell or lipid.
- a specific antigen is a microbe.
- a specific microbe is a virus, bacteria, or fungi.
- Another specific microbe is a virus or a bacteria.
- Bacillus anthracis anthrax
- Listeria monocytogenes Listeria monocytogenes
- Francisella tularensis Listeria monocytogenes
- Salmonella Salmonella
- Salmonella are typhimurium or enteritidis.
- RNA viruses RNA viruses, a product of the RNA virus, or a DNA virus.
- a specific DNA virus is the Hepatitis B virus.
- Specific compounds of the invention have the general formula IA-L-A 1 ; IA-L-(A 1 ) 2 ; IA-L-A 1 -A 1 ; IA-L-A 1 -L-A 1 ; (IA) 2 -L-A 1 -A 1 ; (IA) 2 -L-A 1 -L-A 1 ; (IA) 2 -L-A 1 ; or (IA) 2 -L-(A 1 ) 2 ; wherein IA is as disclosed herein; L is absent or is a linking group; and each A 1 group independently represents an auxiliary group.
- the viral infection is caused by a coronavirus that causes Severe Acute Respiratory Syndrome (SARS), a Hepatitis B virus, or a Hepatitis C Virus.
- SARS Severe Acute Respiratory Syndrome
- Hepatitis B virus a Hepatitis B virus
- Hepatitis C Virus a Hepatitis C virus
- the viral infection is caused by a coronavirus that causes Severe Acute Respiratory Syndrome (SARS), a Hepatitis B virus, or a Hepatitis C Virus.
- SARS Severe Acute Respiratory Syndrome
- Hepatitis B virus a Hepatitis B virus
- Hepatitis C Virus a coronavirus that causes Severe Acute Respiratory Syndrome
- Specific cancers that can be treated include melanoma, superficial bladder cancer, actinic keratoses, intraepithelial neoplasia, and basal cell skin carcinoma, squamous, and the like.
- the method of the invention includes treatment for a precancerous condition such as, for example, actinic keratoses or intraepithelial neoplasia, familial polyposis (polyps), cervical dysplasia, cervical cancers, superficial bladder cancer, and any other cancers associated with infection (e.g., lymphoma Karposi's sarcoma, or leukemia); and the like.
- Non limiting examples of the pathological conditions or symptoms that can be treated include viral diseases, cancer, inflammatory diseases of the gastrointestinal tract, brain, skin, joints, and other tissues.
- the auxiliary groups are believed to enhance the drug activity of the pharmacophore (compounds of formula (I)) by (a) helping to direct the pharmacophore to the receptor within the endosomes of target cells; (b) by enhancing signal transduction induced by the pharmacophore, by cross-linking the receptor; and/or (c) the pharmacophore can enhance the response to the auxiliary group (e.g., immune response).
- the auxiliary groups should form generally stable bonds with the pharmacophore, and do not act as prodrugs.
- IMPDH inosine monophosphate dehydrogenase
- an IMPDH inhibitor refers to an inhibitor of the enzyme inosine monophosphate dehydrogenase.
- IMPDH inhibitors are used clinically: ribavirin, mizoribine, and mycophenolate mofetil.
- Ribavirin and mizoribine are prodrugs that are phosphorylated intracellularly to produce IMP analogs (Goldstein et al., Cuff Med Chem, 6:519-536 (1999)). Viramidine is a prodrug of Ribavirin. Mycophenolate mofetil is immunosuppressive, and has gastrointestinal irritative properties that may be attributable to its enterohepatic recirculation (Papageorgiou C, Mini Rev Med Chem., 1:71-77 (2001)). Mizoribine aglycone, a prodrug, is used as an IMPDH inhibitor. Other non-limiting examples IMPDH inhibitors, including prodrugs of mizoribine and mizoribine aglycone are known and are disclosed in published U.S. Patent application No. 20050004144.
- salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
- Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
- salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
- a sufficiently basic compound such as an amine
- a suitable acid affording a physiologically acceptable anion.
- Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
- the compounds (conjugates) of the invention can be prepared using standard synthetic methods known in the art.
- a general ester synthesis is illustrated below:
- the compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
- the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
- a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier.
- the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
- the amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
- the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
- a liquid carrier such as a vegetable oil or a polyethylene glycol.
- any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and devices.
- the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
- Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
- the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
- the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
- the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
- the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
- Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
- Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
- Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
- the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
- Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
- Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
- Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
- the concentration of the compound(s) of formula I in a liquid composition will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%.
- concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.
- the amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
- a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
- the compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
- the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 ⁇ M, preferably, about 1 to 50 ⁇ M, most preferably, about 2 to about 30 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
- TLR agonist The ability of a compound of the invention to act as a TLR agonist may be determined using pharmacological models which are well known to the art, including the procedures disclosed by Lee et al.; PNAS, 100 p 6646-6651, 2003.
- Sodium salt of 2-methoxyethanol is generated by dissolving sodium metal (81 mg) in 2-methoxyethanol (30 mL) with heat. To this solution is added the product of example 2 (1.0 g) dissolved in methoxyethanol (300 mL, with heat). The reaction mixture is heated for 8 h at 115° C. bath temperature, concentrated in vacuo to near dryness and the residue partitioned between ethyl acetate and water. Flash silica gel chromatography of the organic layer using 5% methanol in dichloromethane gave 763 mg product. NMR is consistent with structure assignment.
- This reducing agent used to convert the nitrile to the aldehyde function is prepared essentially as described in Bull. Korean Chem. Soc . (2002), 23(12), 1697-1698. A 0.5 M solution in dry THF is prepared.
- example 5 The product of example 5 (100 mg) is dissolved in dry THF (3 mL) and cooled to 0° C. under argon.
- the reagent generated in example 6 (0.72 mL) is added to the reaction flask and the mixture is stirred at 0-5° C. for 1 h and then quenched by addition of 3 M HCl.
- the mixture is then extracted with ethyl acetate and then dichloromethane and concentrated in vacuo to yield 85 mg.
- NMR is consistent with structure assignment.
- Example 7 The product of example 7 (800 mg) is combined with sodium iodide (504 mg) and acetonitrile (40 mL), and then chlorotrimethylsilane (0.5 mL) is slowly added. The mixture is heated at 70° C. for 3.5 h, cooled and filtered. The solid product is washed with water, then ether to yield 406 mg. NMR, UV, MS are consistent with structure assignment. This material is suitable for conjugation reactions between linkers and auxiliary groups.
Abstract
Description
where X is a group that can react to form a bond to the linking group or can react to form a bond to the auxiliary group. A specific group of compounds having formula (IA) are disclosed in U.S. Pat. No. 6,329,381.
IA-L-A1;
IA-L-(A1)2;
IA-L-A1-A1;
IA-L-A1-L-A1;
(IA)2-L-A1-A1;
(IA)2-L-A1-L-A1;
(IA)2-L-A1; or
(IA)2-L-(A1)2;
wherein IA is as disclosed herein; L is absent or is a linking group; and each A1 group independently represents an auxiliary group.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/682,208 US9359360B2 (en) | 2005-08-22 | 2012-11-20 | TLR agonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71033705P | 2005-08-22 | 2005-08-22 | |
PCT/US2006/032371 WO2007024707A2 (en) | 2005-08-22 | 2006-08-21 | Tlr agonists |
US6452909A | 2009-02-05 | 2009-02-05 | |
US13/682,208 US9359360B2 (en) | 2005-08-22 | 2012-11-20 | TLR agonists |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/064,529 Continuation US20090324551A1 (en) | 2005-08-22 | 2006-08-21 | Tlr agonists |
PCT/US2006/032371 Continuation WO2007024707A2 (en) | 2005-08-22 | 2006-08-21 | Tlr agonists |
US6452909A Continuation | 2005-08-22 | 2009-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20130165455A1 US20130165455A1 (en) | 2013-06-27 |
US9359360B2 true US9359360B2 (en) | 2016-06-07 |
Family
ID=37772216
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/064,529 Abandoned US20090324551A1 (en) | 2005-08-22 | 2006-08-21 | Tlr agonists |
US13/682,208 Active US9359360B2 (en) | 2005-08-22 | 2012-11-20 | TLR agonists |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/064,529 Abandoned US20090324551A1 (en) | 2005-08-22 | 2006-08-21 | Tlr agonists |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090324551A1 (en) |
EP (1) | EP1931352B1 (en) |
JP (2) | JP2009504803A (en) |
CN (1) | CN101304748A (en) |
CA (1) | CA2620182A1 (en) |
ES (1) | ES2577514T3 (en) |
WO (1) | WO2007024707A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
WO2022003598A1 (en) | 2020-07-02 | 2022-01-06 | Viiv Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
EP4252629A2 (en) | 2016-12-07 | 2023-10-04 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101111085B1 (en) * | 2002-09-27 | 2012-04-12 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Novel adenine compound and use thereof |
US8012964B2 (en) | 2004-03-26 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
WO2007024707A2 (en) | 2005-08-22 | 2007-03-01 | The Regents Of The University Of California | Tlr agonists |
WO2007034817A1 (en) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
EP2029597A4 (en) | 2006-05-31 | 2011-11-23 | Univ California | Purine analogs |
EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
PL2125007T3 (en) | 2007-02-07 | 2014-07-31 | Univ California | Conjugates of synthetic tlr agonists and uses therefor |
PT2125792E (en) * | 2007-02-19 | 2011-03-01 | Glaxosmithkline Llc | Purine derivatives as immunomodulators |
SI2132209T1 (en) * | 2007-03-19 | 2014-05-30 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
US8063051B2 (en) * | 2007-03-19 | 2011-11-22 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators |
JPWO2008114819A1 (en) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | New adenine compounds |
AR065784A1 (en) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES. |
BRPI0811125A2 (en) * | 2007-05-08 | 2017-05-09 | Astrazeneca Ab | imidazoquinolines with immunomodulatory properties |
ES2541434T3 (en) | 2007-06-29 | 2015-07-20 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of the Toll 7 receptor |
WO2009034386A1 (en) * | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
PE20091156A1 (en) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | SALTS OF (3 - {[[3- (6-AMINO-2-BUTOXY-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL) PROPYL] (3-MORFOLIN-4-ILPROPIL) AMINO] METHYL} PHENYL) METHYL ACETATE |
CN102143964A (en) | 2008-01-17 | 2011-08-03 | 大日本住友制药株式会社 | Method for producing adenine compound |
JPWO2009091031A1 (en) * | 2008-01-17 | 2011-05-26 | 大日本住友製薬株式会社 | Method for producing adenine compound |
US20090202626A1 (en) * | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
UA103195C2 (en) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
NZ593110A (en) | 2008-12-09 | 2013-06-28 | Gilead Sciences Inc | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS |
WO2010088395A2 (en) * | 2009-01-30 | 2010-08-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
US8729088B2 (en) | 2009-02-11 | 2014-05-20 | The Regents Of The University Of California | Toll-like receptor modulators and treatment of diseases |
CN102666541B (en) | 2009-10-22 | 2015-11-25 | 吉里德科学公司 | Be used for the treatment of the particularly purine of virus infection or the derivative of deazapurine |
JP2013512859A (en) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | Imidazoquinoline acting through a toll-like receptor (TLR) |
US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
JP6026405B2 (en) | 2010-04-30 | 2016-11-16 | テロルメディクス エセアー | Phospholipid drug analogues |
WO2011134669A1 (en) * | 2010-04-30 | 2011-11-03 | Telormedix Sa | Methods for inducing an immune response |
US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
MX2012013713A (en) | 2010-05-26 | 2013-01-28 | Selecta Biosciences Inc | Nanocarrier compositions with uncoupled adjuvant. |
WO2012038058A1 (en) | 2010-09-21 | 2012-03-29 | Telormedix Sa | Treatment of conditions by toll-like receptor modulators |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
JP5978225B2 (en) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | Imidazo [4,5-c] quinolin-1-yl derivatives useful for therapy |
US8895570B2 (en) | 2010-12-17 | 2014-11-25 | Astrazeneca Ab | Purine derivatives |
US20120231023A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells |
MX2014000872A (en) * | 2011-07-22 | 2014-07-28 | Pawel Kalinski | Tumor selective chemokine modulation. |
US10112946B2 (en) | 2011-07-22 | 2018-10-30 | Glaxosmithkline Llc | Composition |
AR092198A1 (en) | 2012-08-24 | 2015-04-08 | Glaxosmithkline Llc | DERIVATIVES OF PIRAZOLOPIRIMIDINAS |
WO2014052828A1 (en) | 2012-09-27 | 2014-04-03 | The Regents Of The University Of California | Compositions and methods for modulating tlr4 |
AU2013348217B2 (en) | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
ME02867B (en) | 2012-11-20 | 2018-04-20 | Glaxosmithkline Llc | Novel compounds |
WO2014081643A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
JP6356160B2 (en) * | 2013-02-25 | 2018-07-11 | ザ スクリプス リサーチ インスティテュート | Neoceptin: small molecule adjuvant |
US11116774B2 (en) | 2014-07-11 | 2021-09-14 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
US9918959B2 (en) | 2014-08-06 | 2018-03-20 | The Board Of Regents Of The University Of Texas System | TLR-independent small molecule adjuvants |
WO2016023511A1 (en) | 2014-08-15 | 2016-02-18 | 正大天晴药业集团股份有限公司 | Pyrrolopyrimidine compounds used as tlr7 agonist |
AU2015318061B2 (en) | 2014-09-16 | 2018-05-17 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
EA035116B1 (en) | 2015-11-05 | 2020-04-29 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | 7-(thiazol-5-yl)pyrrolopyrimidine as tlr7 receptor agonist |
CN107043380A (en) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | A kind of maleate of TLR7 activators, its crystal formation C, crystal formation D, crystal formation E, preparation method and purposes |
CN107043379A (en) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | A kind of crystal formation A, its preparation method and the medical usage of TLR7 activators |
KR102590454B1 (en) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Antibody-Adjuvant Conjugate |
EP3554550A1 (en) | 2016-12-13 | 2019-10-23 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
ES2939384T3 (en) | 2017-04-14 | 2023-04-21 | Bolt Biotherapeutics Inc | Immunoconjugate synthesis method |
JP2021035910A (en) * | 2017-11-01 | 2021-03-04 | 大日本住友製薬株式会社 | Substituted purine compound |
WO2019196918A1 (en) * | 2018-04-13 | 2019-10-17 | 罗欣药业(上海)有限公司 | Five-membered heterocyclo-pyrimidine compound, pharmaceutical composition and use thereof |
US20210154316A1 (en) | 2018-05-17 | 2021-05-27 | Bolt Biotherapeutics, Inc. | Immunoconjugates |
CN109608462B (en) * | 2018-12-15 | 2021-11-23 | 华南理工大学 | 7-alkyl-9-alkoxy/thiopurine-8-ketone compound, and synthesis method and application thereof in medicines |
CN113993549A (en) | 2019-03-15 | 2022-01-28 | 博尔特生物治疗药物有限公司 | Immunoconjugates targeting HER2 |
US20220347312A1 (en) | 2019-09-04 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Immunoconjugate Synthesis Method |
CN114787165B (en) * | 2020-09-27 | 2023-02-28 | 上海维申医药有限公司 | Macrocyclic TLR7 agonist, preparation method thereof, pharmaceutical composition and application thereof |
CN116600830A (en) | 2020-10-21 | 2023-08-15 | 卢布尔雅那大学 | Conjugated TLR7 and NOD2 agonists |
Citations (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0145340A2 (en) | 1983-11-18 | 1985-06-19 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines |
US4689338A (en) | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
EP0394026A1 (en) | 1989-04-20 | 1990-10-24 | Riker Laboratories, Inc. | Formulation containing an imidazo[4,5-c]quinolin derivative |
US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
WO1992015581A1 (en) | 1991-03-01 | 1992-09-17 | Minnesota Mining And Manufacturing Company | PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES |
EP0553202A1 (en) | 1990-10-05 | 1993-08-04 | Minnesota Mining & Mfg | Process for the preparation of imidazo[4,5-c]quinolin-4-amines. |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
WO1993020847A1 (en) | 1992-04-16 | 1993-10-28 | Minnesota Mining And Manufacturing Company | Vaccine adjuvant |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
US5627281A (en) | 1993-07-15 | 1997-05-06 | Minnesota Mining And Manufacturing Company | Intermediate compounds of fused cycloalkylimidazopyridines |
US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
US5736553A (en) | 1988-12-15 | 1998-04-07 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine |
US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
WO1998017279A1 (en) | 1996-10-25 | 1998-04-30 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
WO1998048805A1 (en) | 1997-04-25 | 1998-11-05 | Sumitomo Pharmaceuticals Company, Limited | Pharmaceutical composition for supressing type 2 helper t cell immune response |
WO1999028321A1 (en) | 1997-11-28 | 1999-06-10 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
JPH11193282A (en) | 1997-12-26 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | Heterocyclic compound |
US6038505A (en) | 1996-09-12 | 2000-03-14 | Siemens Aktiengesellschaft | Method of controlling the drive train of a motor vehicle, and integrated drive train control system |
WO2000043394A1 (en) | 1999-01-26 | 2000-07-27 | Ústav Experimentální Botaniky Av Cr | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
US6245776B1 (en) | 1999-01-08 | 2001-06-12 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
WO2001044260A2 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Novel purines |
WO2001044259A1 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
WO2001049688A1 (en) | 2000-01-07 | 2001-07-12 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
US6333331B1 (en) | 1994-08-01 | 2001-12-25 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted O6-benzylguanines |
WO2002024225A1 (en) | 2000-09-20 | 2002-03-28 | Glaxo Group Limited | Use of immidazoquinolinamines as adjuvants in dna vaccination |
US6372725B1 (en) | 1995-02-16 | 2002-04-16 | Harald Zilch | Specific lipid conjugates to nucleoside diphosphates and their use as drugs |
US20020127224A1 (en) | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US20020193595A1 (en) | 2001-04-09 | 2002-12-19 | Daniel Chu | Novel guanidino compounds |
WO2003077944A1 (en) | 2002-03-19 | 2003-09-25 | Glaxo Group Limited | Improvements in vaccination |
EP1386923A1 (en) | 2001-04-17 | 2004-02-04 | Sumitomo Pharmaceuticals Company, Limited | Novel adenine derivatives |
US20040023211A1 (en) | 2000-09-15 | 2004-02-05 | Kees Groen | System and method for optimizing drug theraphy for the treatment of diseases |
US6706728B2 (en) | 1999-01-08 | 2004-03-16 | 3M Innovative Properties Company | Systems and methods for treating a mucosal surface |
WO2004029054A1 (en) | 2002-09-27 | 2004-04-08 | Sumitomo Pharmaceuticals Company, Limited | Novel adenine compound and use thereof |
US6734187B1 (en) | 1997-11-12 | 2004-05-11 | Mitsubishi Chemical Corporation | Purine derivatives and medicaments comprising the same as active ingredient |
US6733764B2 (en) | 2000-06-14 | 2004-05-11 | Alain Martin | Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer |
US20040091491A1 (en) * | 2002-08-15 | 2004-05-13 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
JP2004137157A (en) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | Medicine comprising new adenine derivative as active ingredient |
US20040209899A1 (en) | 2001-06-29 | 2004-10-21 | Venkata Palle | A2B adenosine receptor antagonists |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
US20050004144A1 (en) | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
JP2005505504A (en) | 2001-05-18 | 2005-02-24 | サーナ・セラピューティクス・インコーポレイテッド | Conjugates and compositions for cellular delivery |
JP2005046160A (en) | 1996-10-25 | 2005-02-24 | Gilead Sciences Inc | Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
US20050049263A1 (en) | 2001-10-30 | 2005-03-03 | Kasibhatla Srinivas Rao | Purine analogs having hsp90-inhibiting activity |
US20050054590A1 (en) | 2003-09-05 | 2005-03-10 | Averett Devron R. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
US20050059613A1 (en) | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
JP2005089334A (en) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | 8-hydroxyadenine compound |
WO2005060966A1 (en) | 2003-12-19 | 2005-07-07 | Sanofi Pasteur | Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist |
WO2005092892A1 (en) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8-oxoadenine compound |
US20050266067A1 (en) | 2004-03-02 | 2005-12-01 | Shiladitya Sengupta | Nanocell drug delivery system |
US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
US20060110746A1 (en) | 2004-11-19 | 2006-05-25 | Institut Gustave Roussy | Treatment of cancer using TLR3 agonists |
WO2006062945A2 (en) | 2004-12-07 | 2006-06-15 | University Of Miami | Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders |
WO2006100226A1 (en) | 2005-03-21 | 2006-09-28 | Ferrer Internacional, S. A. | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
WO2007024707A2 (en) | 2005-08-22 | 2007-03-01 | The Regents Of The University Of California | Tlr agonists |
WO2007034817A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
WO2007034917A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
WO2007038720A2 (en) | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
US20070100146A1 (en) | 2005-11-03 | 2007-05-03 | Trevor Dzwiniel | Process for the preparation of imidazo[4,5-c]-quinolin-4-amines |
US20070161582A1 (en) | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
US20070173483A1 (en) | 2002-10-30 | 2007-07-26 | Conforma Therapeutics Corporation | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors |
US20070190071A1 (en) | 2004-03-26 | 2007-08-16 | Dainippon Sumitomo Pharma Co., Ltd. | 9-Substituted 8-oxoadenine compound |
WO2007142755A2 (en) | 2006-05-31 | 2007-12-13 | The Regents Of The University Of California | Purine analogs |
US20070292418A1 (en) | 2005-04-26 | 2007-12-20 | Eisai Co., Ltd. | Compositions and methods for immunotherapy |
US20080008682A1 (en) | 2006-07-07 | 2008-01-10 | Chong Lee S | Modulators of toll-like receptor 7 |
US20080214580A1 (en) | 2006-10-04 | 2008-09-04 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008115319A2 (en) | 2007-02-07 | 2008-09-25 | Regents Of The University Of California | Conjugates of synthetic tlr agonists and uses therefor |
WO2009005687A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
US20090069289A1 (en) | 2006-10-04 | 2009-03-12 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US20090099212A1 (en) | 2007-10-16 | 2009-04-16 | Jeff Zablocki | A3 adenosine receptor antagonists |
US20090202626A1 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
WO2010093436A2 (en) | 2009-02-11 | 2010-08-19 | Carson Dennis A | Toll-like receptor modulators and treatment of diseases |
US20110098248A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
WO2011139348A2 (en) | 2010-04-30 | 2011-11-10 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
US20110319442A1 (en) | 2009-02-06 | 2011-12-29 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
US20120003298A1 (en) | 2010-04-30 | 2012-01-05 | Alcide Barberis | Methods for inducing an immune response |
US20120009247A1 (en) | 2010-04-30 | 2012-01-12 | Roberto Maj | Phospholipid drug analogs |
US20120083473A1 (en) | 2010-09-21 | 2012-04-05 | Johanna Holldack | Treatment of conditions by toll-like receptor modulators |
US20120177681A1 (en) | 2010-09-01 | 2012-07-12 | Manmohan Singh | Formulation of immunopotentiators |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (en) | 1983-08-30 | 1985-04-24 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
-
2006
- 2006-08-21 WO PCT/US2006/032371 patent/WO2007024707A2/en active Application Filing
- 2006-08-21 ES ES06813535.9T patent/ES2577514T3/en active Active
- 2006-08-21 EP EP06813535.9A patent/EP1931352B1/en not_active Not-in-force
- 2006-08-21 CN CNA200680038761XA patent/CN101304748A/en active Pending
- 2006-08-21 CA CA002620182A patent/CA2620182A1/en not_active Abandoned
- 2006-08-21 JP JP2008528017A patent/JP2009504803A/en active Pending
- 2006-08-21 US US12/064,529 patent/US20090324551A1/en not_active Abandoned
-
2012
- 2012-11-20 JP JP2012254043A patent/JP2013040209A/en active Pending
- 2012-11-20 US US13/682,208 patent/US9359360B2/en active Active
Patent Citations (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4689338A (en) | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
EP0310950A1 (en) | 1983-11-18 | 1989-04-12 | Riker Laboratories, Inc. | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes |
EP0145340A2 (en) | 1983-11-18 | 1985-06-19 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US5736553A (en) | 1988-12-15 | 1998-04-07 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
EP0389302A1 (en) | 1989-03-23 | 1990-09-26 | Riker Laboratories, Inc. | Olefinic 1H-imidazo [4,5-c]quinolin-4-amines |
US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
EP0394026A1 (en) | 1989-04-20 | 1990-10-24 | Riker Laboratories, Inc. | Formulation containing an imidazo[4,5-c]quinolin derivative |
EP0553202A1 (en) | 1990-10-05 | 1993-08-04 | Minnesota Mining & Mfg | Process for the preparation of imidazo[4,5-c]quinolin-4-amines. |
US5367076A (en) | 1990-10-05 | 1994-11-22 | Minnesota Mining And Manufacturing Company | Process for imidazo[4,5-C]quinolin-4-amines |
US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
EP0575549A1 (en) | 1991-03-01 | 1993-12-29 | Minnesota Mining & Mfg | PROCESS FOR IMIDAZO 4,5-c]QUINOLIN-4-AMINES. |
WO1992015581A1 (en) | 1991-03-01 | 1992-09-17 | Minnesota Mining And Manufacturing Company | PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES |
WO1993020847A1 (en) | 1992-04-16 | 1993-10-28 | Minnesota Mining And Manufacturing Company | Vaccine adjuvant |
US6083505A (en) | 1992-04-16 | 2000-07-04 | 3M Innovative Properties Company | 1H-imidazo[4,5-C]quinolin-4-amines as vaccine adjuvants |
EP0636031A1 (en) | 1992-04-16 | 1995-02-01 | Minnesota Mining & Mfg | Vaccine adjuvant. |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
EP0681570A1 (en) | 1993-01-29 | 1995-11-15 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
EP0708773A1 (en) | 1993-07-15 | 1996-05-01 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5627281A (en) | 1993-07-15 | 1997-05-06 | Minnesota Mining And Manufacturing Company | Intermediate compounds of fused cycloalkylimidazopyridines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5444065A (en) | 1993-07-15 | 1995-08-22 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines as inducer of interferon α biosynthesis |
US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US6333331B1 (en) | 1994-08-01 | 2001-12-25 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted O6-benzylguanines |
US6372725B1 (en) | 1995-02-16 | 2002-04-16 | Harald Zilch | Specific lipid conjugates to nucleoside diphosphates and their use as drugs |
US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
EP0912564A1 (en) | 1996-06-21 | 1999-05-06 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahydroimidazoquinolinamines |
US6624305B2 (en) | 1996-06-21 | 2003-09-23 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
EP0912565A1 (en) | 1996-06-21 | 1999-05-06 | Minnesota Mining And Manufacturing Company | Process for preparing imidazoquinolinamines |
US6613902B2 (en) | 1996-06-21 | 2003-09-02 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US6534654B2 (en) | 1996-06-21 | 2003-03-18 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US6437131B1 (en) | 1996-06-21 | 2002-08-20 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US5998619A (en) | 1996-06-21 | 1999-12-07 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
US6150523A (en) | 1996-06-21 | 2000-11-21 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
US6897314B2 (en) | 1996-06-21 | 2005-05-24 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US6038505A (en) | 1996-09-12 | 2000-03-14 | Siemens Aktiengesellschaft | Method of controlling the drive train of a motor vehicle, and integrated drive train control system |
US6200592B1 (en) | 1996-10-25 | 2001-03-13 | 3M Innovative Properties Company | Immine response modifier compounds for treatment of TH2 mediated and related diseases |
JP2005046160A (en) | 1996-10-25 | 2005-02-24 | Gilead Sciences Inc | Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
US6696076B2 (en) | 1996-10-25 | 2004-02-24 | 3M Innovative Properties Company | Immune response modifier compounds for treatment of TH2 mediated and related diseases |
US6610319B2 (en) | 1996-10-25 | 2003-08-26 | 3M Innovative Properties Company | Immune response modifier compounds for treatment of TH2 mediated and related diseases |
WO1998017279A1 (en) | 1996-10-25 | 1998-04-30 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
EP0938315A1 (en) | 1996-10-25 | 1999-09-01 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
US6039969A (en) | 1996-10-25 | 2000-03-21 | 3M Innovative Properties Company | Immune response modifier compounds for treatment of TH2 mediated and related diseases |
WO1998048805A1 (en) | 1997-04-25 | 1998-11-05 | Sumitomo Pharmaceuticals Company, Limited | Pharmaceutical composition for supressing type 2 helper t cell immune response |
US6734187B1 (en) | 1997-11-12 | 2004-05-11 | Mitsubishi Chemical Corporation | Purine derivatives and medicaments comprising the same as active ingredient |
US6329381B1 (en) | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
EP1035123A1 (en) * | 1997-11-28 | 2000-09-13 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
WO1999028321A1 (en) | 1997-11-28 | 1999-06-10 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
JPH11193282A (en) | 1997-12-26 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | Heterocyclic compound |
US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US6706728B2 (en) | 1999-01-08 | 2004-03-16 | 3M Innovative Properties Company | Systems and methods for treating a mucosal surface |
US6245776B1 (en) | 1999-01-08 | 2001-06-12 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
WO2000043394A1 (en) | 1999-01-26 | 2000-07-27 | Ústav Experimentální Botaniky Av Cr | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
US6552192B1 (en) | 1999-01-26 | 2003-04-22 | Ustau Experimentalni Botaniky Av-Cr | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
US20030191086A1 (en) | 1999-01-26 | 2003-10-09 | Ustav Experimentalni Botaniky Av Cr | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
WO2001044260A2 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Novel purines |
WO2001044259A1 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
WO2001049688A1 (en) | 2000-01-07 | 2001-07-12 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
US6733764B2 (en) | 2000-06-14 | 2004-05-11 | Alain Martin | Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer |
US20040023211A1 (en) | 2000-09-15 | 2004-02-05 | Kees Groen | System and method for optimizing drug theraphy for the treatment of diseases |
WO2002024225A1 (en) | 2000-09-20 | 2002-03-28 | Glaxo Group Limited | Use of immidazoquinolinamines as adjuvants in dna vaccination |
US20020127224A1 (en) | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
US20050038027A1 (en) | 2001-04-09 | 2005-02-17 | Chiron Corporation | Novel guanidino compounds |
US6716840B2 (en) | 2001-04-09 | 2004-04-06 | Chiron Corporation | Guanidino compounds |
US7189727B2 (en) | 2001-04-09 | 2007-03-13 | Chiron Corporation | Guanidino compounds |
US6960582B2 (en) | 2001-04-09 | 2005-11-01 | Chiron Corporation | Guanidino compounds |
US20020193595A1 (en) | 2001-04-09 | 2002-12-19 | Daniel Chu | Novel guanidino compounds |
US20040248895A1 (en) | 2001-04-09 | 2004-12-09 | Daniel Chu | Novel guanidino compounds |
US20040132748A1 (en) | 2001-04-17 | 2004-07-08 | Yoshiaki Isobe | Novel adenne derivatives |
EP1386923A1 (en) | 2001-04-17 | 2004-02-04 | Sumitomo Pharmaceuticals Company, Limited | Novel adenine derivatives |
US7521454B2 (en) | 2001-04-17 | 2009-04-21 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine derivatives |
US7157465B2 (en) | 2001-04-17 | 2007-01-02 | Dainippon Simitomo Pharma Co., Ltd. | Adenine derivatives |
US20070037832A1 (en) | 2001-04-17 | 2007-02-15 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine derivatives |
JP2005505504A (en) | 2001-05-18 | 2005-02-24 | サーナ・セラピューティクス・インコーポレイテッド | Conjugates and compositions for cellular delivery |
US20040209899A1 (en) | 2001-06-29 | 2004-10-21 | Venkata Palle | A2B adenosine receptor antagonists |
US7238700B2 (en) | 2001-06-29 | 2007-07-03 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US20050049263A1 (en) | 2001-10-30 | 2005-03-03 | Kasibhatla Srinivas Rao | Purine analogs having hsp90-inhibiting activity |
US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
US20080125446A1 (en) | 2001-10-30 | 2008-05-29 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
WO2003077944A1 (en) | 2002-03-19 | 2003-09-25 | Glaxo Group Limited | Improvements in vaccination |
US20040091491A1 (en) * | 2002-08-15 | 2004-05-13 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
US20060052403A1 (en) | 2002-09-27 | 2006-03-09 | Yoshiaki Isobe | Novel adenine compound and use thereof |
WO2004029054A1 (en) | 2002-09-27 | 2004-04-08 | Sumitomo Pharmaceuticals Company, Limited | Novel adenine compound and use thereof |
EP1550662A1 (en) * | 2002-09-27 | 2005-07-06 | Sumitomo Pharmaceuticals Company, Limited | Novel adenine compound and use thereof |
US7754728B2 (en) | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
JP2004137157A (en) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | Medicine comprising new adenine derivative as active ingredient |
US20070173483A1 (en) | 2002-10-30 | 2007-07-26 | Conforma Therapeutics Corporation | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
US20050004144A1 (en) | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
US20050059613A1 (en) | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
US20070161582A1 (en) | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
US20050054590A1 (en) | 2003-09-05 | 2005-03-10 | Averett Devron R. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
JP2007504232A (en) | 2003-09-05 | 2007-03-01 | アナディス ファーマシューティカルズ インク | Administration of TLR7 ligand and prodrug thereof for the treatment of hepatitis C virus infection |
US7576068B2 (en) | 2003-09-05 | 2009-08-18 | Anadys Pharmaceuticals, Inc. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
WO2005025583A2 (en) | 2003-09-05 | 2005-03-24 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
US8211863B2 (en) | 2003-09-05 | 2012-07-03 | Anadys Pharmaceuticals, Inc. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
JP2005089334A (en) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | 8-hydroxyadenine compound |
US20070087009A1 (en) | 2003-12-19 | 2007-04-19 | Sanofi Pasteur | Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist |
WO2005060966A1 (en) | 2003-12-19 | 2005-07-07 | Sanofi Pasteur | Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist |
US20050266067A1 (en) | 2004-03-02 | 2005-12-01 | Shiladitya Sengupta | Nanocell drug delivery system |
US20070190071A1 (en) | 2004-03-26 | 2007-08-16 | Dainippon Sumitomo Pharma Co., Ltd. | 9-Substituted 8-oxoadenine compound |
WO2005092892A1 (en) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8-oxoadenine compound |
US20060110746A1 (en) | 2004-11-19 | 2006-05-25 | Institut Gustave Roussy | Treatment of cancer using TLR3 agonists |
WO2006062945A2 (en) | 2004-12-07 | 2006-06-15 | University Of Miami | Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders |
WO2006100226A1 (en) | 2005-03-21 | 2006-09-28 | Ferrer Internacional, S. A. | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
US20070292418A1 (en) | 2005-04-26 | 2007-12-20 | Eisai Co., Ltd. | Compositions and methods for immunotherapy |
JP2009504803A (en) | 2005-08-22 | 2009-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | TLR agonist |
WO2007024707A3 (en) | 2005-08-22 | 2007-09-20 | Univ California | Tlr agonists |
US20090324551A1 (en) | 2005-08-22 | 2009-12-31 | The Regents Of The University Of California Office Of Technology Transfer | Tlr agonists |
WO2007024707A2 (en) | 2005-08-22 | 2007-03-01 | The Regents Of The University Of California | Tlr agonists |
WO2007034917A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
US20090105212A1 (en) | 2005-09-22 | 2009-04-23 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
WO2007034817A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
EP1939202A1 (en) | 2005-09-22 | 2008-07-02 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
JP2009510096A (en) | 2005-09-27 | 2009-03-12 | コーリー ファーマシューティカル ゲーエムベーハー | Modulation of TLR-mediated immune responses using adapter oligonucleotides |
WO2007038720A2 (en) | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
US20070100146A1 (en) | 2005-11-03 | 2007-05-03 | Trevor Dzwiniel | Process for the preparation of imidazo[4,5-c]-quinolin-4-amines |
US20130190494A1 (en) | 2006-05-31 | 2013-07-25 | The Regents Of The University Of California | Purine analogs |
WO2007142755A3 (en) | 2006-05-31 | 2008-10-02 | Univ California | Purine analogs |
WO2007142755A2 (en) | 2006-05-31 | 2007-12-13 | The Regents Of The University Of California | Purine analogs |
AU2007257423B2 (en) | 2006-05-31 | 2012-02-09 | The Regents Of The University Of California | Purine analogs |
US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
US20110098294A1 (en) | 2006-05-31 | 2011-04-28 | Carson Dennis A | Purine analogs |
US20090202484A1 (en) | 2006-07-07 | 2009-08-13 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
US20080008682A1 (en) | 2006-07-07 | 2008-01-10 | Chong Lee S | Modulators of toll-like receptor 7 |
US20080214580A1 (en) | 2006-10-04 | 2008-09-04 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US20090069289A1 (en) | 2006-10-04 | 2009-03-12 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008115319A3 (en) | 2007-02-07 | 2009-03-05 | Dennis A Carson | Conjugates of synthetic tlr agonists and uses therefor |
US20140302120A1 (en) | 2007-02-07 | 2014-10-09 | The Regents Of The University Of California | Conjugates of synthetic tlr agonists and uses therefor |
US8790655B2 (en) | 2007-02-07 | 2014-07-29 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and uses therefor |
WO2008115319A2 (en) | 2007-02-07 | 2008-09-25 | Regents Of The University Of California | Conjugates of synthetic tlr agonists and uses therefor |
US8357374B2 (en) | 2007-02-07 | 2013-01-22 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and uses therefor |
US20120148660A1 (en) | 2007-02-07 | 2012-06-14 | Regents Of The University Of California, San Diego Ucsd Technology Transfer Office | Conjugates of synthetic tlr agonists and uses therefor |
HK1138767A1 (en) | 2007-02-07 | 2010-09-03 | Univ California | Conjugates of synthetic tlr agonists and uses therefor |
US20130156807A1 (en) | 2007-02-07 | 2013-06-20 | The Regents Of The University Of California | Conjugates of synthetic tlr agonists and uses therefor |
WO2009005687A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
US7968544B2 (en) | 2007-06-29 | 2011-06-28 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
US20090047249A1 (en) | 2007-06-29 | 2009-02-19 | Micheal Graupe | Modulators of toll-like receptor 7 |
US20090099212A1 (en) | 2007-10-16 | 2009-04-16 | Jeff Zablocki | A3 adenosine receptor antagonists |
WO2009099650A3 (en) | 2008-02-07 | 2009-10-22 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
US20090202626A1 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
WO2009099650A2 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
WO2009099650A4 (en) | 2008-02-07 | 2010-01-14 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
US20110319442A1 (en) | 2009-02-06 | 2011-12-29 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
EP2396328A2 (en) | 2009-02-11 | 2011-12-21 | The Regents of The University of California | Toll-like receptor modulators and treatment of diseases |
US8729088B2 (en) | 2009-02-11 | 2014-05-20 | The Regents Of The University Of California | Toll-like receptor modulators and treatment of diseases |
US20100210598A1 (en) | 2009-02-11 | 2010-08-19 | Regents Of The University Of California, San Diego | Toll-like receptor modulators and treatment of diseases |
JP2012517428A (en) | 2009-02-11 | 2012-08-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Toll-like receptor modulators and disease treatment |
WO2010093436A2 (en) | 2009-02-11 | 2010-08-19 | Carson Dennis A | Toll-like receptor modulators and treatment of diseases |
US20110098248A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
JP2013525431A (en) | 2010-04-30 | 2013-06-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Use of phospholipid conjugates of synthetic TLR7 agonists |
US20120009247A1 (en) | 2010-04-30 | 2012-01-12 | Roberto Maj | Phospholipid drug analogs |
US20120003298A1 (en) | 2010-04-30 | 2012-01-05 | Alcide Barberis | Methods for inducing an immune response |
WO2011139348A2 (en) | 2010-04-30 | 2011-11-10 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
US20120177681A1 (en) | 2010-09-01 | 2012-07-12 | Manmohan Singh | Formulation of immunopotentiators |
US20120083473A1 (en) | 2010-09-21 | 2012-04-05 | Johanna Holldack | Treatment of conditions by toll-like receptor modulators |
Non-Patent Citations (250)
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
EP4252629A2 (en) | 2016-12-07 | 2023-10-04 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
US11426566B2 (en) | 2016-12-14 | 2022-08-30 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a TLR modulator |
WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
WO2022003598A1 (en) | 2020-07-02 | 2022-01-06 | Viiv Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
Also Published As
Publication number | Publication date |
---|---|
EP1931352A4 (en) | 2011-11-23 |
JP2013040209A (en) | 2013-02-28 |
WO2007024707A3 (en) | 2007-09-20 |
EP1931352B1 (en) | 2016-04-13 |
AU2006283524A2 (en) | 2008-06-05 |
US20090324551A1 (en) | 2009-12-31 |
CA2620182A1 (en) | 2007-03-01 |
CN101304748A (en) | 2008-11-12 |
AU2006283524A1 (en) | 2007-03-01 |
JP2009504803A (en) | 2009-02-05 |
US20130165455A1 (en) | 2013-06-27 |
WO2007024707A2 (en) | 2007-03-01 |
ES2577514T3 (en) | 2016-07-15 |
EP1931352A2 (en) | 2008-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9359360B2 (en) | TLR agonists | |
ES2456964T3 (en) | Conjugates of synthetic TLR agonists and their uses | |
US8846697B2 (en) | Purine analogs | |
US9441005B2 (en) | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds | |
AU2006283524B2 (en) | TLR agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA SAN DIEGO;REEL/FRAME:029355/0995 Effective date: 20121126 |
|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARSON, DENNIS A;GRIMSHAW, SUZANNE;COTTAM, HOWARD B.;AND OTHERS;SIGNING DATES FROM 20080626 TO 20080627;REEL/FRAME:031569/0593 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |